Fusion Antibodies (LON:FAB) Stock Price Up 12.8% – What’s Next?

Shares of Fusion Antibodies plc ( LON:FAB – Get Free Report ) rose 12.8% during trading on Thursday . The stock traded as high as GBX 7.

95 ($0.10) and last traded at GBX 7.95 ($0.



10). Approximately 981,343 shares were traded during trading, a decline of 16% from the average daily volume of 1,166,639 shares. The stock had previously closed at GBX 7.

05 ($0.09). Fusion Antibodies Stock Up 25.

6 % The company has a debt-to-equity ratio of 2.40, a quick ratio of 2.36 and a current ratio of 3.

87. The firm’s 50 day moving average price is GBX 5.48 and its two-hundred day moving average price is GBX 4.

19. The company has a market cap of £9.76 million, a P/E ratio of -255.

85 and a beta of 0.49. Insiders Place Their Bets In other news, insider Adrian Kinkaid purchased 83,728 shares of the business’s stock in a transaction on Wednesday, October 16th.

The shares were acquired at an average price of GBX 4 ($0.05) per share, for a total transaction of £3,349.12 ($4,160.

40). Corporate insiders own 11.39% of the company’s stock.

About Fusion Antibodies Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. Featured Stories Receive News & Ratings for Fusion Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Antibodies and related companies with MarketBeat.

com's FREE daily email newsletter ..